Barcoded Medication Administration: A Last Line of Defense von Cescon, David W, Etchells, Edward

Volltext

Abstract ES13-3: Novel epigenomic targets in TNBC von Cescon, DW

Volltext

Targeting the cell cycle in breast cancer: towards the next phase von Thu, KL, Soria-Bretones, I, Mak, TW, Cescon, DW

Volltext

Abstract P5-14-05: Capecitabine in early breast cancer: A meta-analysis of randomized controlled trials von Natori, A, Ethier, J-L, Amir, E, Cescon, DW

Volltext

Abstract OT3-04-03: KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine the... von Cardoso, F, Bardia, A, Andre, F, Cescon, DW, McArthur, H, Telli, M, Loi, S, Cortés, J, Schmid, P, Harbeck, N, Denkert, C, Jackisch, C, Jia, L, Tryfonidis, K, Karantza, V

Volltext

Abstract OT1-12-01: Exploration of factors associated with imminent risk of late recurrence in hormone receptor positive breast cancer von Jerzak, KJ, Cescon, DW, Chia, SK, Bratman, S, Ennis, M, Stambolic, V, Chang, M, Dowling, R, Goodwin, PJ

Volltext

Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area von Booth, Christopher M, Matukas, Larissa M, Tomlinson, George A, Rachlis, Anita R, Rose, David B, Dwosh, Hy A, Walmsley, Sharon L, Mazzulli, Tony, Avendano, Monica, Derkach, Peter, Ephtimios, Issa E, Kitai, Ian, Mederski, Barbara D, Shadowitz, Steven B, Gold, Wayne L, Hawryluck, Laura A, Rea, Elizabeth, Chenkin, Jordan S, Cescon, David W, Poutanen, Susan M, Detsky, Allan S

Volltext

Abstract P1-16-03: Phase II randomized clinical trial (RCT) of metformin (MET) vs placebo (PLAC) in combination with chemotherapy (CXT) in refractory locally advanced (LABC) or met... von Goodwin, PJ, Ennis, M, Cescon, DW, Elser, C, Haq, R, Hamm, CM, Lohmann, AE, Pimentel, I, Chang, MC, Dowling, RJ, Stambolic, V

Volltext

Abstract P2-09-14: Association between BMI and residual estradiol levels in post-menopausal women using adjuvant letrozole: Results of a prospective study von Cescon, DW, Ennis, M, Pritchard, KI, Townsley, C, Warr, D, Elser, C, Rao, L, Stambolic, V, Sridhar, S, Goodwin, PJ

Volltext

Abstract P5-12-02: Effect of 5 vs 2.5 mg/day letrozole on residual estrogen levels in post-menopausal women with high BMI - A prospective crossover study von Cescon, DW, Ennis, M, Pritchard, KI, Townsley, C, Warr, D, Elser, C, Rao, L, Stambolic, V, Sridhar, S, Goodwin, PJ

Volltext

Abstract PD6-10: KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1–positive, previously untreated, metastatic triple-negative breast cancer (mTNBC) von Adams, S, Loi, S, Toppmeyer, DL, Cescon, DW, De Laurentiis, M, Nanda, R, Winer, EP, Mukai, H, Tamura, K, Armstrong, AC, Liu, MC, Iwata, H, Ryvo, L, Wimberger, P, Rugo, HS, Tan, A, D'Aquanno, C, Ding, Y, Karantza, V, Schmid, P

Volltext

Abstract P5-13-09: Feasibility of a Randomized Controlled Trial of Vitamin D vs. Placebo in Recently Diagnosed Breast Cancer Patients von Cescon, DW, Ganz, PA, Hallak, S, Ennis, M, Mills, BK, Goodwin, PJ

Volltext

892 Non-redundant mechanisms of resistance to immunotherapy and radiotherapy converge on innate immunity von Nguyen, Anthony T, Dar, Tahir B, Viramontes, Jolene, Stevens, Satchel, Jang, Julie, Ko, Emily, Chung, Eric M, Zhang, Samuel, Atkins, Katelyn M, Kamrava, Mitchell, Sandler, Howard M, Guarnerio, Jlenia, Knott, Simon, Zumsteg, Zachary, Underhill, David M, Shiao, Stephen L

Volltext

94 Effects of chemoimmunotherapy on the peripheral blood: insights from immune monitoring of a phase Ib trial of pembrolizumab and paclitaxel or capecitabine for triple-negative br... von Chun, Brie, Pucilowska, Joanna, Chang, Shu Ching, Kim, Isaac, Nikitin, Benjamin, Koguchi, Yoshinobu, Redmond, William, Bernard, Brady, Rajamanickam, Venkatesh, Polaske, Nathan, Fields, Paul, Conrad, Valerie, Schmidt, Mark, Urba, Walter, Conlin, Alison, McArthur, Heather, Page, David

Volltext

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer von Cortes, Javier, Rugo, Hope S., Cescon, David W., Im, Seock-Ah, Yusof, Mastura M., Gallardo, Carlos, Lipatov, Oleg, Barrios, Carlos H., Perez-Garcia, Jose, Iwata, Hiroji, Masuda, Norikazu, Torregroza Otero, Marco, Gokmen, Erhan, Loi, Sherene, Guo, Zifang, Zhou, Xuan, Karantza, Vassiliki, Pan, Wilbur, Schmid, Peter

Volltext

APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation von Cescon, David W, Haibe-Kains, Benjamin, Mak, Tak W

Volltext

Development of novel agents for the treatment of early estrogen receptor positive breast cancer von Elliott, Mitchell J., Cescon, David W.

Volltext

Pembrolizumab monotherapy in metastatic triple-negative breast cancer von Amir, Eitan, Cescon, David W

Volltext

Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer von Thu, K. L., Silvester, J., Elliott, M. J., Ba-alawi, W., Duncan, M. H., Elia, A. C., Mer, A. S., Smirnov, P., Safikhani, Z., Haibe-Kains, B., Mak, T. W., Cescon, D. W.

Volltext

Can a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor-Positive Early Breast Cancer? von Cescon, David W, Kalinsky, Kevin, DeMichele, Angela M

Volltext